XNYS · Healthcare · Drug Manufacturers - General
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q2 2026 | 0.81 | -0.01 | -100.86% | $0 | ❌ Miss | +0.00% | +1.85% | — |
| 2026-08-04 | Q2 2026 | 0.81 | 0.96 | +18.64% | $12.21B | ✅ Beat | +0.98% | +6.53% | — |
| 2026-05-13 |
| Q1 2026 |
| 0.87 |
| -0.00 |
| -100.23% |
| $0 |
| ❌ Miss |
| +0.13% |
| -4.27% |
| -6.80% |
| 2026-02-04 | Q4 2025 | 0.89 | 1.00 | +12.36% | $12.34B | ✅ Beat | -5.37% | +3.28% | -18.25% |
| 2025-11-05 | Q3 2025 | 0.77 | 1.03 | +33.38% | $11.74B | ✅ Beat | — | — | — |
| 2025-08-06 | Q2 2025 | 0.93 | 0.91 | -2.15% | $11.68B | ❌ Miss | — | — | — |
| 2025-02-05 | Q4 2024 | 0.83 | 0.91 | +9.64% | $12.26B | ✅ Beat | +1.68% | -4.60% | +1.68% |
| 2024-11-06 | Q3 2024 | 0.88 | 0.90 | +2.27% | $10.50B | ✅ Beat | +2.15% | +1.47% | +5.13% |
Showing last 8 quarters.